louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06954012: Effect of STRAIN COUNTER-STRAIN ON PATIENTS WITH ANKLE SPRAINS
Official title: Effect of STRAIN COUNTER-STRAIN ON PATIENTS WITH ACUTE and POSTACUTE LATERAL ANKLE SPRAINS
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Sports Medicine Injuries
Keywords: COUNTER-STRAIN, LATERAL ANKLE SPRAINS, positional release,
effect STRAIN COUNTER-STRAIN ankle sprain
Lead sponsor: Al-Ahliyya Amman University
Sponsor class: OTHER
First posted: 2025-05-01
Enrollment: 36
Sex: ALL
Minimum age (years): 15
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: patients (male and female) will be participate at the study complain of acute to subacute ankle sprain.

Orthopedic surgeons who will be responsible for the diagnosis of the all cases. The patients will under went to anterior drawer test .

Detailed description: Age, six, height, weight (Between 15 to 40 y).

1. FAAM TEST
2. single-leg loading (SLL) test, fOR proprioception
3. Knee to Wall Dorsiflexion Lunge Test for Ankle dorsiflexion ROM. From sitting.(MODIFIED).
4. Pain (VAS)

Eligibility criteria: Inclusion Criteria:

acute to subacute ankle sprain positive ankle anterior drawer test

Exclusion Criteria:

* Recurrent ankle sprain,

Primary outcomes:
measure: assess Pain changes
timeFrame: At base line and after 3months of treatment
Secondary outcomes:
measure: The Foot and Ankle Ability Measure(FAAM TEST)
timeFrame: At base line and after 3months of treatment
measure: Changes of Knee to Wall Dorsiflexion Lunge Test
timeFrame: at base line and after 3month of treatment
measure: changes of single-leg loading (SLL) test
timeFrame: at base line and after 3month of treatment
Other outcomes:
Locations:
city: Amman
country: Jordan
facility: Al-Ahliyya Amman University
city: Amman
country: Jordan
facility: Hossam Metwally
Study officials:
References:
Clinical trial NCT05636046: Transseptal Italian Registry (TITLE)
Official title: Transseptal Catheterization Registry. An Italian Overview
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Arrhythmia
Cardiac Disease
Keywords: Catheter ablation
Transseptal catheterization
Lead sponsor: Luigi Sacco University Hospital
Sponsor class: OTHER
First posted: 2022-12-05
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all patients underwent trasseptal catheterization for catheter ablation of arrhythmias in the left heart

Brief summary: The goal of this observational study is to learn about the changing over the time of transseptal (TSP) catheterization for catheter ablation of arrhythmias in the left heart. This study aims to investigate if auxiliary tools for TSP catheterization improved the safety and efficacy.

Detailed description: Data regarding transseptal catheterization in the Centers involved will be retrospectively collected over the past 10 years.

Will be collected:

1) patients characteristics

1. type of procedure requiring transseptal catheterization
2. success rate
3. adverse events
4. use of tools for transseptal catheterization:

   * intracardiac echocardiography (ICE) guidance
   * simplified transseptal puncture
   * "pig tail" catheter
   * "safe sept" guidewire
   * powered radiofrequency transseptal needle

Eligibility criteria: Inclusion Criteria:

* patients underwent transseptal catheterization of left side heart interventional procedures (catheter ablation)

Exclusion Criteria:

* patients with learning disabilities

Primary outcomes:
measure: Adverse events related to inadvertent puncture cardiac structures other than atrial septum
timeFrame: Procedure time
measure: Accomplishment of transseptal catheterization and electrophysiology procedure requiring transseptal catheterization
timeFrame: Procedure time
Secondary outcomes:
Other outcomes:
Locations:
city: Ancona
country: Italy
facility: Presidio Ospedaliero G. Salesi
city: Bologna
country: Italy
facility: Ospedale Policlinico Sant'Orsola-Malpighi
city: Brescia
country: Italy
facility: Spedali Civili di Brescia
city: Desenzano Del Garda
country: Italy
facility: Ospedale Desenzano del Garda
city: Milano
country: Italy
facility: Ospedale San Raffaele
city: Milan
country: Italy
facility: Centro Cardiologico Monzino
city: Milan
country: Italy
facility: Luigi Sacco University Hospital
city: Monza
country: Italy
facility: Ospedale San Gerardo
city: Roma
country: Italy
facility: Ospedale Policlinico Universitario Agostino Gemelli
city: Varese
country: Italy
facility: Ospedale Di Circolo e Fondazione Macchi
Study officials:
References:
Clinical trial NCT04382846: Novel Regimens in COVID-19 Treatment
Official title: Nitazoxanide in Treatment of COVID-19
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: COVID
Corona Virus Infection
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2020-05-11
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

Detailed description: Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019. Some studies demonstrated the efficacy of combined regimen of nitazoxanide and azithromycin or ivermectin and chloroquine.

Eligibility criteria: Inclusion Criteria:

* Patients with COVID-19 infection

Exclusion Criteria:

* Allergy or contraindication to the drugs.

Primary outcomes:
measure: Number of patients with virological cure
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University, Assiut University
city: Tanta
country: Egypt
facility: Sherief Abd-Elsalam
Study officials:
affiliation: ass. Prof. Tropical Medicine
name: sherief Abd-Elsalam, Ass. Prof.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kelleni MT. Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacol Res. 2020 Jul;157:104874. doi: 10.1016/j.phrs.2020.104874. Epub 2020 Apr 30.
citation: Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020 Apr 22;35:100684. doi: 10.1016/j.nmni.2020.100684. eCollection 2020 May.
Clinical trial NCT00247546: Prevention of Falls and Injurious Falls Among Elderly People
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Falls
Accidental Falls
Keywords: Falls
Accidental falls
Prevention
Aged
Multifactorial trial
Lead sponsor: The Hospital District of Satakunta
Sponsor class: OTHER
First posted: 2005-11-02
Enrollment: 592
Sex: ALL
Minimum age (years): 65
Maximum age (years): 85
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The aim of this study is to describe and analyse the effects of multifactorial trial on the incidence of falls and injurious falls and on different risk factors of falling among the home-dwelling aged.

Detailed description: The aims of the study:

1. To implement a program for the prevention of falls and injurious falls.
2. To describe the structure and activities of the fall prevention program implemented among the aged who are living in their own home, have at least moderate cognitive abilities, have fallen during previous 12 months and are 65 years of age or older. A further aim is to describe the frequency of participation according to age, gender, residence, health and physical condition.
3. To describe the effects of prevention on primary risk factors of falling such as muscle strength, balance, eye sight, medications, depression and home hazards in relation to age, gender, health and physical condition.
4. To describe and assess the effects of prevention on the incidence of falls and injurious falls.
5. To assess the effects of prevention on physical, cognitive and psychosocial functional abilities, quality of life and use of health and social services and deaths.

Eligibility criteria: Inclusion Criteria:

* 65 years of age or older
* home-dweller
* having fallen at least once during the previous 12 months
* at least moderate cognitive abilities (MMSE over 17)
* able to walk 10 metres independently

Exclusion Criteria:

* MMSE under 17

Primary outcomes:
measure: Incidence of falls and injurious falls
Secondary outcomes:
measure: Risk factors of falling
measure: Functional abilities
measure: Quality of life
measure: Use of health and social services
measure: Deaths
Other outcomes:
Locations:
city: Pori
country: Finland
facility: The Hospital District of Satakunta
Study officials:
affiliation: The Hospital District of Satakunta
name: Sirkka-Liisa Kivelä, Professor
role: STUDY_DIRECTOR
References:
citation: Salminen M, Vahlberg T, Kivela SL. The long-term effect of a multifactorial fall prevention programme on the incidence of falls requiring medical treatment. Public Health. 2009 Dec;123(12):809-13. doi: 10.1016/j.puhe.2009.10.018.
Clinical trial NCT05476146: Re-routing in Treatment High Anal Fistula
Official title: Re-routing of the Track in the Treatment of High Anal Fistula
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Anal Fistula
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2022-07-27
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the role of rereouting in treatment of high anal fistula and evaluate the success rate, the recurrence and incontinence and see if rerouting of the track is a good choice in treatment of high anal fistula?

Detailed description: Anal fistula is a very common perianal condition associated with considerable morbidity and inconvenience to the patient. It is hollow tract lined with granulation tissue that connects an in-depth primary opening inside the anal canal to a superficial secondary opening in the perianal skin. It is mostly nonspecific infection of an anal gland in the intersphincteric space as the initiating pathology Different classifications have been put forward which categorize these Fistula into low or high simple or complex, or according to their anatomy into intersphincteric, trans-sphincteric, and supra-sphincteric or extra-sphincteric Surgical therapy is the main method used to treat anal fistula. The best treatment criterion is to eradicate the infected lesion, ensure sufficient drainage, and promote the closure of the fistula, while minimizing damage to the anal sphincter.

High anal fistulas require more complex treatment when compared to low anal fistula because of their complexity.

Rerouting is a transposition technique for the management of high anal and anorectal fistulae is described by Mann and Clifton in 1985. The method involves re-routing the extrasphincteric portion of the track into an intersphincteric position with immediate repair of the external sphincter. The newly posi-tioned intersphincteric fistula is then dealt with at a later date when the external sphincter is soundly healed .

The advantages of rerouting over other techniques in patients with high anal fistulae; patients had satisfactory results, decrease recurrence of fistulae or abscess formation. Healing is rapid, short hospital stay and continence to flatus and faeces preserved

Eligibility criteria: Inclusion Criteria:- patients with high anal fistula admitted at Asuit University Hospital at the period of study

Exclusion Criteria:- Any case with low anal fistula

Primary outcomes:
measure: evaluation the role of rerouting of the track in high anal fistula in treatemt
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02900846: Colour Doppler Flow Imaging in Lacrimal Gland Lesions
Official title: Usefulness of Colour Doppler Flow Imaging in the Management of Lacrimal Gland Lesions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lacrimal Tumor
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2016-09-14
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients suffering from lacrimal fossa tumors explored with ultrasonography including doppler flow imaging

Brief summary: Retrospective medical charts and medical imaging files review of patients suffering from lacrimal fossa lesions who underwent ocular ultrasonography with color flow doppler imaging.


Eligibility criteria: Inclusion Criteria:

* Patients suffering from lacrimal fossa tumor
* Orbital ultrasonography performed, including doppler flow imaging
* Histopathological characterization of the tumor obtained after surgical removal

Exclusion Criteria:

* Absence of histopathological characterization
* Absence of documented ultrasound doppler flow imaging

Primary outcomes:
measure: Pulsed wave doppler resistance index in tumor vascularization
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00204646: Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)
Official title: Phase II Study of Neoadjuvant Dose-Intensive Chemotherapy With Adriamycin and Ifosfamide Followed by High-Dose ICE in Locally Advanced Soft Tissue Sarcomas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Sarcoma, Soft Tissue
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2005-09-20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Complete resection is still the only curative treatment option in patients with soft tissue sarcoma (STS). Patients with a non-resectable STS have a dismal prognosis even without evidence of metastatic disease. The aim of this trial is to determine whether neoadjuvant dose-intensive chemo-radiotherapy is a feasible and effective approach in patients with non-resectable STS.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed STS with locally advanced non-resectable disease
* Metastatic disease is allowed in case of solitary resectable metastases
* Grading according to Coindre \> II°
* Measurable tumor lesions
* Age \> 18 through 65 years
* Karnofsky status \> 70 %
* Written informed consent

Exclusion Criteria:

* Prior chemotherapy
* Intercurrent disease interfering with the adequate administration of study medication including severe psychological disease
* Insufficient liver-, renal or bone marrow function
* Evidence of pregnancy
* Treatment within another clinical trial
* Uncontrolled viral Infections (HIV,HBV, HCV)
* other malignancies

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: Medical Center II, University of Tuebingen
Study officials:
affiliation: South West German Cancer Center, Medical Center II, University of Tuebingen
name: Joerg T. Hartmann, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00523146: Treatment of Primary Menstrual Pain With Kanion Capsule
Official title: Treatment of Primary Dysmenorrhea With Kanion Capsule (GF) A Randomized, Double-blind, Placebo-controlled, Repeated-Dose and Multi-Center Clinical Phase II Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Primary Dysmenorrhea
Keywords: primary dysmenorrhea
Herbal remedy
Lead sponsor: Lianyungang Kanion Group, Ltd.
Sponsor class: INDUSTRY
First posted: 2007-08-31
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objectives of this clinical trial are:

* To further study the safety of Kanion Capsule (GF) in primary dysmenorrhea subjects;
* To further evaluate the efficacy of GF in treatment of primary dysmenorrhea.


Eligibility criteria: Inclusion Criteria:

* primary dysmenorrhea

Exclusion Criteria:

* secondary dysmenorrhea

Primary outcomes:
measure: pain reduction
timeFrame: 6 months
Secondary outcomes:
measure: accompanying symptoms improvement
timeFrame: 6 months
Other outcomes:
Locations:
city: Sandy Springs
country: United States
facility: Mount Vernon Clinical Research, LLC
state: Georgia
Study officials:
affiliation: Biokey Inc.
name: Jun Shao, Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT06559046: A CT-BASED Deep Learning Model for Predicting WHO/ISUP Pathological Grades of Clear Cell Renal Cell Carcinoma (ccRCC) :A Multicenter Cohort Study
Official title: A CT-BASED Deep Learning Model for Predicting WHO/ISUP Pathological Grades of Clear Cell Renal Cell Carcinoma (ccRCC) :A Multicenter Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tumor Grading
Deep Learning
Clear Cell Renal Cell Carcinoma
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2024-08-19
Enrollment: 483
Sex: ALL
Minimum age (years): 30
Maximum age (years): 88
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study recruited three cohorts of patients with pathologically diagnosed ccRCC, including a total of 483 patients who underwent nephrectomy or partial nephrectomy

Brief summary: This study aims to establish an effective deep learning model to extract relevant information about renal tumors and kidneys from computed tomography (CT) images and predict the pathological grades of clear cell renal cell carcinoma (ccRCC).

Retrospective data were collected from 483 ccRCC patients across three medical centers. Arterial phase and portal venous phase CT images from the dataset were segmented for renal tumors and kidneys. Three convolutional neural networks (CNNs) were employed to extract features from the regions of interest (ROI) in the CT images across multiple dimensions including 3D, 2.5D, and 2D. Least absolute shrinkage and selection (LASSO) regression was used for feature selection. The models were evaluated using receiver operating characteristic (ROC) curves and decision curve analysis (DCA).


Eligibility criteria: Inclusion Criteria:

* Patients with a single kidney tumor have complete imaging and clinical data
* Contrast-enhanced CT scan within 30 days before surgery
* No treatment was performed before CT examination

Exclusion Criteria:

* Patients with tumor recurrence
* Obvious artifacts on CT images
* The tumor is cystic
* Multiple cysts on the affected kidney affect the delineation of renal parenchyma

Primary outcomes:
measure: predict the pathological grades of clear cell renal cell carcinoma (ccRCC)
timeFrame: 2019-2024
measure: predict the pathological grades of clear cell renal cell carcinoma (ccRCC)
timeFrame: 2019-2024
Secondary outcomes:
Other outcomes:
Locations:
city: Jinhua
country: China
facility: Department of Urology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua,Zhejiang, China
state: Zhejiang
Study officials:
References:
Clinical trial NCT03359512: Comparison of Two Electroencephalograms (EEG) Monitors in Patients Undergoing General Anesthesia With Sevoflurane
Official title: Comparison of Two Electroencephalograms (EEG) Monitors in Patients Undergoing General Anesthesia With Sevoflurane
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: General Anesthesia
Keywords: anesthesia monitoring
Lead sponsor: Hopital Foch
Sponsor class: OTHER
First posted: 2017-12-02
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Quantium Medical Company has an ElectoEcenphalograph-based (EEG-based) algorithm with two outputs: qCON for unconsciousness and qNOX for anti-nociception. qCON, is designed to provide information about the depth of the hypnotic state, similar to that provided by the BIS™.


Eligibility criteria: Inclusion Criteria:

* Patients affiliated to a national insurance scheme or benefiting from such a program
* Patients having given their written consent.
* Patients that must benefit from a general anesthesia with the aim of a surgical act of a duration of at least one hour
* Patients that must benefit from a general anesthesia including a maintenance by the sevoflurane.
* For the patients taken care in ambulatory surgery, having a telephone and agreeing to communicate their phone number

Exclusion Criteria:

* Pregnant or breast-feeding Women
* Patients having a limit of use of the Bispectral Index (BIS) or qCON monitor ,
* Patients having a contraindication in the propofol.
* Patients taken care in ambulatory surgery who could not be contacted within 24 hours following the surgical operation;

Primary outcomes:
measure: qCON monitoring during maintenance of anesthesia
timeFrame: up to 10 hours
Secondary outcomes:
measure: BIS monitoring during maintenance of anesthesia
timeFrame: One day
measure: qCON monitoring during induction of anesthesia
timeFrame: One day
measure: BIS monitoring during induction of anesthesia
timeFrame: One day
measure: qCON monitoring during recovery of anesthesia
timeFrame: One day
measure: BIS monitoring during recovery of anesthesia during recovery of anesthesia
timeFrame: One day
measure: Burst Suppression ratio retrieved by qCON monitoring
timeFrame: One day
measure: Burst Suppression ratio retrieved by BIS monitoring
timeFrame: One day
measure: qNOX monitoring during anesthesia
timeFrame: One day
measure: Periods of loss of signal of qCON
timeFrame: One day
measure: Periods of loss of signal of BIS during anesthesia
timeFrame: One day
Other outcomes:
Locations:
city: Suresnes
country: France
facility: Hopital Foch
Study officials:
affiliation: Hopital Foch
name: Faiz Sofian, MD
role: PRINCIPAL_INVESTIGATOR
References: